Allyx Therapeutics is a clinical-stage biotechnology company developing regenerative medicine therapies aimed at restoring neuronal function in patients with neurodegenerative diseases. Their approach focuses on enhancing cognitive health by targeting the underlying mechanisms of neurodegeneration.
Funding
$9.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NIFounders
Product
Problem
Neurodegenerative diseases, such as Alzheimer's and Parkinson's, lead to progressive neuronal damage and synaptic dysfunction, resulting in cognitive decline and impaired motor function. Current treatments primarily address symptoms without effectively targeting the underlying mechanisms of neurodegeneration or promoting neuronal regeneration.
Solution
Allyx Therapeutics is developing regenerative medicine therapies designed to restore neuronal function in patients with neurodegenerative diseases. Their lead compound, ALX-001, is designed to enhance cognitive health by targeting the mechanisms of neurodegeneration and promoting synaptic plasticity. ALX-001 has demonstrated safety and tolerability in Phase 1 clinical trials and is advancing into Phase 2 studies for Alzheimer's and Parkinson's disease. The company's approach focuses on preserving and protecting synapses, the connections between neurons, to slow or reverse the progression of these debilitating conditions. By addressing the root causes of neurodegeneration, Allyx aims to provide disease-modifying treatments that improve patient outcomes.
Target Audience
The primary target audience includes patients diagnosed with neurodegenerative diseases such as Alzheimer's and Parkinson's, as well as neurologists and other healthcare providers specializing in the treatment of these conditions.
Features
- ALX-001: A novel therapeutic compound targeting synaptic dysfunction in neurodegenerative diseases.
- Oral administration: Demonstrated safety and tolerability in Phase 1 clinical trials with oral dosing.
- Phase 2 clinical trials: Advancing ALX-001 into Phase 2 studies for Alzheimer's and Parkinson's disease.
- Synapse protection: Designed to preserve and protect synapses to slow or reverse disease progression.
- mGluR5 modifier: ALX-001 modulates mGluR5 receptors, which play a key role in synaptic plasticity and neuronal signaling.